<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht005012.v1" study_id="phs000892.v2" participant_set="2" date_created="Tue Sep 29 12:14:47 2015"><description>Participant ID, race, ethnicity, gender, participant history of malignancy, number of tubes with plasma, detection of nodal involvement, method used for specimens, blood collection time, normal samples, participant procurement age, tumor sample 1, 2, 3, 4, 5, anesthesia time, Case Report Form, ER, HER1, ERBB2, tumor histology, lymph nodes involvement, tumor stage, progesterone receptor, micro metastasis, age at diagnosis, pathologic diagnosis, chemotherapy, lumpectomy, mastectomy, radiation therapy of participants with breast cancer and involved in the "Clinical Proteomic Tumor Analysis Consortium (CPTAC) Proteogenomic Confirmatory Study of Breast, Colon, Lung, and Ovarian Tumors" project.</description><unique_key phv="00253075" version="1">Participant_ID</unique_key><unique_key phv="00253076" version="1">CRF_Name</unique_key><variable id="phv00253075.v1"><name>Participant_ID</name><description>De-Identified subject (participant) ID, from the pre-printed labels that are part of the procurement package provided by the BCR</description><type>string</type></variable><variable id="phv00253076.v1"><name>CRF_Name</name><description>Information collected on Case Report Form (CRF) at |Submission, Baseline, 1 year follow up, 5 year follow up]</description><type>string</type></variable><variable id="phv00253077.v1"><name>Participant_Procurement_Age</name><description>Participant age in months at the time of tissue procurement</description><type>integer</type><unit>Months</unit></variable><variable id="phv00253078.v1"><name>Participant_Gender</name><description>Participant gender using the defined categories [Male, Female, Unknown, Unspecified]</description><type>string</type></variable><variable id="phv00253079.v1"><name>Participant_Race</name><description>Participant race using the defined categories. Options = American Indian or Alaska Native; Asian; White; Black or African American; Native Hawaiian or other Pacific Islander; Not Evaluated; Unknown (Could not be determined or unsure)</description><type>string</type></variable><variable id="phv00253080.v1"><name>Participant_Ethnicity</name><description>Ethnicity using the defined categories [Not Hispanic or Latino; Hispanic or Latino; Not Evaluated; Unknown]</description><type>string</type></variable><variable id="phv00253081.v1"><name>Participant_History_Malignancy</name><description>Indicate whether the participant was, at any time in their life, diagnosed with a malignancy prior to the diagnosis of the specimen submitted for CPTAC.  If the participant has had a prior malignancy, an additional form (the Other Malignancy Form) must be completed for each prior malignancy. (If this question cannot be answered because the answer is unknown, the case will be excluded from CPTAC. If the participant has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types). [No; Yes, Only Non-melanomatous Skin Cancer Within the Last Year; Yes, Only In Situ Cervical Cancer Within the Last Year;  Yes, Only Non-melanomatous Skin Cancer and In Situ Cervical Cancer Within the Last Year; Yes, History of Other Cancer Greater Than One Year Ago]</description><type>string</type></variable><variable id="phv00253082.v1"><name>Participant_History_Chemotherapy</name><description>Did participant ever received systematic chemotherapy for any previous cancer [Yes; No]</description><type>string</type></variable><variable id="phv00253083.v1"><name>Participant_History_Neo-adjuvant_Treatment</name><description>Did participant received therapy for this cancer prior to sample procurement of the tumor submitted for CPTAC.  If the participant did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instructions.(Note: Systemic treatment and certain localized therapies (those administered to the same site as the CPTAC submitted tissue) given prior to procurement of the sample submitted for CPTAC are exclusionary). [Yes; No]</description><type>string</type></variable><variable id="phv00253084.v1"><name>Participant_History_Radiation_Therapy</name><description>Indicate whether the participant ever received radiation therapy involving the breast [Yes; No]</description><type>string</type></variable><variable id="phv00253085.v1"><name>Participant_History_Lumpectomy_Mastectomy_or_Port_Placement</name><description>Indicate whether this participant underwent lumpectomy/mastectomy or port placement [Lumpectomy/Mastectomy; Port Placement]</description><type>string</type></variable><variable id="phv00253086.v1"><name>Aliquots_Plasma</name><description>Number of tubes of plasma obtained from the participant</description><type>integer</type></variable><variable id="phv00253087.v1"><name>Blood_Collection_Time</name><description>The 24-hr clock time on the day of when the CPTAC blood sample(s) was/were collected from the participant.</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253088.v1"><name>Blood_Collection_Method</name><description>Method for obtaining the blood sample [Venipuncture (Vacutainer Apparatus); Venipuncture (Syringe); Venipuncture (Syringe); IV Catheter ]</description><type>string</type></variable><variable id="phv00253089.v1"><name>Anesthesia_Time</name><description>Time when anesthesia was administered to the participant.</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253090.v1"><name>Tissue_Sampling_Method</name><description>Indicate whether the tissue was obtained via coring or via surgical excision [Coring; Excision]</description><type>string</type></variable><variable id="phv00253091.v1"><name>Biopsy_Device</name><description>Provide the type of biopsy device used (e.g., 10g Bard biopsy device)</description><type>string</type></variable><variable id="phv00253092.v1"><name>Tumor_Sample_Number</name><description>Number of tumor excisional segments or cores obtained</description><type>integer</type></variable><variable id="phv00253093.v1"><name>Tumor_Sample_1_Excision_Time</name><description>The 24-hr clock time when tumor segment 1 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253094.v1"><name>Tumor_Sample_1_Weight</name><description>Weight of tumor segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253095.v1"><name>Tumor_Sample_1_Comments</name><description>Comments regarding the gross appearance of the tumor excisional segment or core</description><type>string</type></variable><variable id="phv00253096.v1"><name>Tumor_Sample_1_LN2_Time</name><description>The 24-hour clock time when tumor segment 1 was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253097.v1"><name>Tumor_Sample_1_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253098.v1"><name>Tumor_Sample_2_Excision_Time</name><description>The 24-hr clock time when tumor segment 2 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253099.v1"><name>Tumor_Sample_2_Weight</name><description>Weight of tumor segment in mg</description><type>"</type><unit>number</unit><value>mg</value></variable><variable id="phv00253100.v1"><name>Tumor_Sample_2_Comments</name><description>Comments regarding the gross appearance of the tumor excisional segment or core</description><type>string</type></variable><variable id="phv00253101.v1"><name>Tumor_Sample_2_LN2_Time</name><description>The 24-hour clock time when the tumor segment 2 was immersed in LN2 vapor.</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253102.v1"><name>Tumor_Sample_2_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and Surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253103.v1"><name>Tumor_Sample_3_Excision_Time</name><description>The 24-hr clock time when tumor segment 3 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253104.v1"><name>Tumor_Sample_3_Weight</name><description>Weight of tumor segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253105.v1"><name>Tumor_Sample_3_Comments</name><description>Comments regarding the gross appearance of the tumor excisional segment or core</description><type>string</type></variable><variable id="phv00253106.v1"><name>Tumor_Sample_3_LN2_Time</name><description>The 24-hour clock time when the tumor sample or portion  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253107.v1"><name>Tumor_Sample_3_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and Surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253108.v1"><name>Tumor_Sample_4_Excision_Time</name><description>The 24-hr clock time when tumor segment 4 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253109.v1"><name>Tumor_Sample_4_Weight</name><description>Weight of tumor segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253110.v1"><name>Tumor_Sample_4_Comments</name><description>Comments regarding the gross appearance of the tumor excisional segment or core</description><type>string</type></variable><variable id="phv00253111.v1"><name>Tumor_Sample_4_LN2_Time</name><description>The 24-hour clock time when the tumor sample or portion  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253112.v1"><name>Tumor_Sample_4_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253113.v1"><name>Tumor_Sample_5_Excision_Time</name><description>The 24-hr clock time when tumor segment 5 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253114.v1"><name>Tumor_Sample_5_Weight</name><description>Weight of tumor segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253115.v1"><name>Tumor_Sample_5_Comments</name><description>Comments regarding the gross appearance of the tumor excisional segment or core</description><type>string</type></variable><variable id="phv00253116.v1"><name>Tumor_Sample_5_LN2_Time</name><description>The 24-hour clock time when the tumor sample or portion  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253117.v1"><name>Tumor_Sample_5_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253118.v1"><name>Normal_Sample_Number</name><description>Specify the number of normal segments that were removed and saved to the CPTAC-provided cryomolds</description><type>"</type><unit>integer</unit><value>Number of normal segments</value></variable><variable id="phv00253119.v1"><name>Normal_Sample_1_Excision_Time</name><description>The 24-hr clock time when normal segment 1 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253120.v1"><name>Normal_Sample_1_Weight</name><description>Weight of normal segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253121.v1"><name>Normal_Sample_1_Comments</name><description>Comments regarding the gross appearance of the normal segment or core</description><type>string</type></variable><variable id="phv00253122.v1"><name>Normal_Sample_1_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253123.v1"><name>Normal_Sample_1_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253124.v1"><name>Normal_Sample_2_Excision_Time</name><description>The 24-hr clock time when normal segment 2 was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253125.v1"><name>Normal_Sample_2_Weight</name><description>Weight of normal segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253126.v1"><name>Normal_Sample_2_Comments</name><description>Comments regarding the gross appearance of the normal segment or core</description><type>string</type></variable><variable id="phv00253127.v1"><name>Normal_Sample_2_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253128.v1"><name>Normal_Sample_2_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical excision time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253129.v1"><name>Normal_Sample_3_Excision_Time</name><description>The 24-hr clock time when normal segment was excised</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253130.v1"><name>Normal_Sample_3_Weight</name><description>Weight of normal segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253131.v1"><name>Normal_Sample_3_Comments</name><description>Comments regarding the gross appearance of the normal segment or core</description><type>string</type></variable><variable id="phv00253132.v1"><name>Normal_Sample_3_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253133.v1"><name>Normal_Sample_3_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical devascularization time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253134.v1"><name>Normal_Sample_4_Excision_Time</name><description>The 24-hr clock time when normal tissue sample was devascularized</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253135.v1"><name>Normal_Sample_4_Weight</name><description>Weight of normal segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253136.v1"><name>Normal_Sample_4_Comments</name><description>Comments regarding the gross appearance of the normal segment or core</description><type>string</type></variable><variable id="phv00253137.v1"><name>Normal_Sample_4_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253138.v1"><name>Normal_Sample_4_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical devascularization time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253139.v1"><name>Normal_Sample_5_Excision_Time</name><description>The 24-hr clock time when normal tissue sample was devascularized</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253140.v1"><name>Normal_Sample_5_Weight</name><description>Weight of normal segment in mg</description><type>number</type><unit>mg</unit></variable><variable id="phv00253141.v1"><name>Normal_Sample_5_Comments</name><description>Comments regarding the gross appearance of the normal segment or core</description><type>string</type></variable><variable id="phv00253142.v1"><name>Normal_Sample_5_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor</description><type>integer</type><unit>(HR(24):MN)</unit></variable><variable id="phv00253143.v1"><name>Normal_Sample_5_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and surgical devascularization time</description><type>integer</type><unit>Minutes</unit></variable><variable id="phv00253144.v1"><name>Histological_Subtype</name><description>Using the participant pathology/laboratory report, select the histology and/or subtype of the tumor submitted for CPTAC. (Note: All other subtypes not listed are excluded from this study.) [Infiltrating Ductal Carcinoma; Infiltrating Lobular Carcinoma; Infiltrating Carcinoma NOS; Mucinous Carcinoma; Medullary Carcinoma; Mixed Histology, specify; Other, specify]</description><type>string</type></variable><variable id="phv00253145.v1"><name>Histological_Subtype_Mixed_or_Other</name><description>Specify mixed histology or other histological subtype</description><type>string</type></variable><variable id="phv00253146.v1"><name>Initial_Diagnosis_Age_Months</name><description>Provide the age of the participant in months, at the time the participant was initially pathologically diagnosed</description><type>integer</type><unit>Months</unit></variable><variable id="phv00253147.v1"><name>Method_of_Pathologic_Diagnosis</name><description>Provide the procedure used to initially diagnose the participant [Excisional Biopsy; Incisional Biopsy; Tumor resection]</description><type>string</type></variable><variable id="phv00253148.v1"><name>Method_of_Pathologic_Diagnosis_Other</name><description>If the procedure used to initially diagnose the participant was not included in the list provided, please describe the method used</description><type>string</type></variable><variable id="phv00253149.v1"><name>Axillary_Staging_Method</name><description>Using the pathology/laboratory report, provide the axillary staging method used to detect nodal involvement [Sentinel node biopsy alone; Axillary lymph node dissection alone; Sentinel lymph node biopsy plus axillary dissection; No axillary staging; Other (specify)]</description><type>string</type></variable><variable id="phv00253150.v1"><name>Axillary_Staging_Method_Other</name><description>If the axillary staging method used was not included in the list provided, please describe the method used</description><type>string</type></variable><variable id="phv00253151.v1"><name>IHC_Staining_Used</name><description>Indicate whether immunohistochemistry (IHC) staining was performed to detect micro metastasis [Yes; No;  Unknown; NA]</description><type>string</type></variable><variable id="phv00253152.v1"><name>Lymph_Nodes_Examined</name><description>Indicate whether any lymph nodes were examined at the time of the primary resection. If the tumor tissue supplied to CPTAC was obtained using vacuum-assisted coring, enter NA and skip the rest of this section. [Yes; No; Unknown; NA]</description><type>string</type></variable><variable id="phv00253153.v1"><name>Lymph_Nodes_Examined_Number</name><description>Provide the number of lymph nodes examined, if one or more lymph nodes were removed</description><type>integer</type></variable><variable id="phv00253154.v1"><name>Lymph_Nodes_Positive_Hematoxylin_Eosin_Staining_Number</name><description>Provide the number of lymph nodes positive through hematoxylin and eosin (H&amp;E) staining and light microscopy</description><type>integer</type></variable><variable id="phv00253155.v1"><name>Lymph_Nodes_Positive_IHC_Keratin_Staining_Number</name><description>Provide the number of lymph nodes positive through keratin immunohistochemistry (IHC) staining</description><type>integer</type></variable><variable id="phv00253156.v1"><name>Pathologic_T_Stage</name><description>Using the participant pathology/laboratory report, select the code for the pathologic T (primary tumor) defined by the American Joint Committee on Cancer (AJCC). If the tumor tissue supplied to CPTAC was obtained using vacuum-assisted coring, you may skip this section if appropriate [T0; T1; T1a; T1b; T1c; T1mi; T2; T2a; T2b; T3; T3a; T3b; T4; T4b; T4c; T4d; Tis; TX; Tis (DCIS); Tis (LCIS); Tis (Paget's)]</description><type>string</type></variable><variable id="phv00253157.v1"><name>Pathologic_N_Stage</name><description>Using the participant pathology/laboratory report, select the code for the pathologic N (nodal) defined by the American Joint Committee on Cancer (AJCC). [N0; N1; N1a; N1b; N1c; N2; N2a; N2b; N3; N3a; N3b; N3c; NX; N1mi; N1bIV; N1BIII; N1bII; N1bI; N0 (mol+); N0 (mol-); N0 (i+); N0 (i-)]</description><type>string</type></variable><variable id="phv00253158.v1"><name>Pathologic_M_Stage</name><description>Using the participant pathology/laboratory report, select the code for the pathologic M (metastasis) defined by the American Joint Committee on Cancer (AJCC).  [MX;  cM0 (i+); M0; M1]</description><type>string</type></variable><variable id="phv00253159.v1"><name>Pathologic_Stage</name><description>Using the participant pathology/laboratory report, select the stage defined by the American Joint Committee on Cancer (AJCC). The patient must be Stage IIA-IIIC to be included in the CPTAC study. [Stage X; Stage 0; Stage I; Stage IA; Stage IB; Stage II; Stage IIA; Stage IIB; Stage IIC; Stage III; Stage IIIA; Stage IIIB; Stage IV; Stage Tis]</description><type>string</type></variable><variable id="phv00253160.v1"><name>Estrogen_Receptor_Status_by_IHC</name><description>If IHC estrogen receptor testing was performed, provide the result of the test.  If this test was not performed, select "not performed", and continue to the progesterone receptor questions. If this test was performed but not available, select "Performed but Not Available" and continue to the progesterone receptor questions. [Positive; Negative; Indeterminate; Borderline; Performed but Not Available; Not performed; Unknown]</description><type>string</type></variable><variable id="phv00253161.v1"><name>Estrogen_Receptor_IHC_Percent_Positive</name><description>If IHC estrogen receptor testing was performed, provide the percent of estrogen receptor positive by IHC.  [&lt;1%; 1-10%; 10-19%; 20-29%; 30-39%; 40-49%; 50-59%; 60-69%; 70-79%; 80-89%; 90-100%]</description><type>string</type></variable><variable id="phv00253162.v1"><name>Estrogen_Receptor_IHC_Positivity_Intensity_Scale</name><description>Using the pathology/laboratory report, indicate the intensity scale used for the estrogen receptor positivity score. [4 Point Scale; 3 Point Scale]</description><type>string</type></variable><variable id="phv00253163.v1"><name>Estrogen_Receptor_IHC_Positivity_Score</name><description>Provide the positivity score using the IHC intensity scale, found on the pathology/laboratory report. [Unknown; 0; 1+; 2+; 3+; 4+; Other (specify)]</description><type>string</type></variable><variable id="phv00253164.v1"><name>Estrogen_Receptor_IHC_Positivity_Other_Scale</name><description>If another scale was used to measure the estrogen receptor positivity, please describe the scale used.</description><type>string</type></variable><variable id="phv00253165.v1"><name>Estrogen_Receptor_IHC_Positivity_Other_Method_Description</name><description>If a special method was used to calculate estrogen receptor status (e.g. dextran coated charcoal), describe the method used.</description><type>string</type></variable><variable id="phv00253166.v1"><name>Progesterone_Receptor_Status_by_IHC</name><description>If IHC progesterone receptor testing was performed, provide the result of the test.  If this test was not performed, select "Not Performed,"  or "Unknown" and continue to the HER2/ERBB2 IHC questions. [Positive; Negative; Indeterminate; Borderline; Performed but Not Available; Not performed; Unknown]</description><type>string</type></variable><variable id="phv00253167.v1"><name>Progesterone_Receptor_IHC_Percent_Positive</name><description>If IHC progesterone receptor testing was performed, provide the percent of progesterone receptor positive nuclei by IHC. [&lt;1%; 1-10%; 10-19%; 20-29%; 30-39%; 40-49%; 50-59%; 60-69%; 70-79%; 80-89%; 90-100%]</description><type>string</type></variable><variable id="phv00253168.v1"><name>Progesterone_Receptor_IHC_Positivity_Intensity_Scale</name><description>Using the pathology/laboratory report, indicate the intensity scale used for the progesterone receptor positivity score. [4 Point Scale; 3 Point Scale]</description><type>string</type></variable><variable id="phv00253169.v1"><name>Progesterone_Receptor_IHC_Positivity_Score</name><description>Provide the positivity score using the IHC intensity scale, found on the pathology/laboratory report. Only answer this question if PR status is considered positive; if the PR status was negative, continue to the HER2/ERBB2 IHC questions. [Unknown; 0; 1+; 2+; 3+; 4+; Other (specify)]</description><type>string</type></variable><variable id="phv00253170.v1"><name>Progesterone_Receptor_IHC_Positivity_Other_Scale</name><description>If another scale was used to measure the progesterone receptor positivity, please describe the scale used.</description><type>string</type></variable><variable id="phv00253171.v1"><name>Progesterone_Receptor_IHC_Positivity_Other_Method_Description</name><description>If a special method was used (other than IHC) to calculate progesterone receptor status (e.g. dextran coated charcoal), describe the method used.</description><type>string</type></variable><variable id="phv00253172.v1"><name>HER2_ERBB2_Status_by_IHC</name><description>If IHC HER2/ERBB2 testing was performed, provide the result of the test.  If this test was not performed or unknown, select "Not Performed" or "Unknown", and continue to the HER2/ERBB2 FISH questions. [Positive; Negative; Indeterminate; Borderline; Performed but Not Available; Not performed; Unknown]</description><type>string</type></variable><variable id="phv00253173.v1"><name>HER2_ERBB2_Statusr_IHC_Percent_Positive</name><description>If IHC HER2/ERBB2 testing was performed, provide the percent of HER2/ERBB2 positive by IHC.  If HER2/ERBB2 was negative, continue to the HER2/ERBB2 FISH questions. [&lt;10%; 10-19%; 20-29%; 30-39%; 40-49%; 50-59%; 60-69%; 70-79%; 80-89%; 90-100%; less than 10%]</description><type>string</type></variable><variable id="phv00253174.v1"><name>HER2_ERBB2_Status_IHC_Positivity_Score</name><description>Provide the positivity score using the IHC intensity scale, found on the pathology/laboratory report. [Unknown; 0; 1+; 2+; 3+; 4+; Other (specify)]</description><type>string</type></variable><variable id="phv00253175.v1"><name>HER2_ERBB2_Status_IHC_Positivity_Other_Scale</name><description>If an additional scale was used to measure HER2/ERBB2 positivity, please describe the scale used.</description><type>string</type></variable><variable id="phv00253176.v1"><name>HER2_ERBB2_Status_IHC_Positivity_Other_Method_Description</name><description>If a special method was used to calculate HER2/ERBB2 status, describe the method used.</description><type>string</type></variable><variable id="phv00253177.v1"><name>HER2_ERBB2_Status_by_FISH</name><description>If HER2/ERBB2 FISH testing was performed, provide the result of the test.  If this test was not performed, select "Not Performed." [Positive; Negative; Indeterminate; Borderline; Performed but Not Available; Not performed; Unknown]</description><type>string</type></variable><variable id="phv00253178.v1"><name>HER2_ERBB2_Status_FISH_Average_Signals</name><description>If HER2 copy number testing was performed by FISH, provide the average number of HER2 FISH signals for this participant.  If this test was not performed, leave this question blank and move to the next question</description><type>Integer</type></variable><variable id="phv00253179.v1"><name>HER2_ERBB2_Status_FISH_Centromere17_Signals</name><description>If Centromere 17 copy number testing was performed by FISH, provide the average number of Centromere 17 signals for this patient.  If this test was not performed, leave this question blank and move to the next question</description><type>Integer</type></variable><variable id="phv00253180.v1"><name>HER2_ERBB2_Status_FISH_Centromere17_Cell_Counts</name><description>Indicate the total number of cells counted by FISH for HER2 &amp; Centromere 17 copy numbers.  If these tests were not performed, leave this question blank and move to the next question</description><type>Integer</type></variable><variable id="phv00253181.v1"><name>HER2_ERBB2_Status_FISH_Centromere17_Ratio</name><description>If HER2 copy number and Centromere 17 copy number testing was performed by FISH, provide the ratio of the outcomes of these tests. (For example, if both the HER2 copy number and the Centromere 17 copy number equal 2, the ratio would be 2.2 or 1.0.)</description><type>number</type></variable><variable id="phv00253182.v1"><name>HER2_ERBB2_Status_FISH_Centromere17_Other_Scale</name><description>If an additional scale was used to measure HER2 &amp; Centromere 17 positivity, please describe the scale used</description><type>string</type></variable><variable id="phv00253183.v1"><name>HER2_ERBB2_Status_Positivity_Other_Method_Description</name><description>If a special method was used to calculate HER2 &amp; Centromere 17 positivity, describe the method used</description><type>string</type></variable></data_table>
